Investing Profile

Bali Muralidhar

InvestorVC

Managing Partner at Abingworth

abingworth.com/team/bali-mura...London

Your Intro Paths to Bali Muralidhar

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Bali Muralidhar on

cb

Current Investing Position

Abingworth Managing Partner

Investment Range

$15.0M - $30.0M

Sweet Spot

$22.5M

Investments On Record

10

Current Fund Size

$465M

Bali Muralidhar is on these Sector & Stage Rankings

Pharmaceuticals (Series A)Pharmaceuticals (Seed)BioTech (Series A)Health & Hospital Services (Series A)Health IT (Series A)Health & Hospital Services (Seed)BioTech (Seed)Health IT (Seed)Pharmaceuticals (Series A)London Pharmaceuticals (Seed)BioTech (Series A)Health & Hospital Services (Series A)BioTech (Seed)Health & Hospital Services (Seed)Health IT (Seed)Health IT (Series A)

Bali Muralidhar's Investments On Record (10)

Company	StageDateRound Size	Total Raised
Ascend Gene & Cell Therapies	Series AMay 2023$66M	$66M
Anjarium Biosciences	Series ASep 2021$60M	$60M
CymaBay Therapeutics	Post Ipo DebtAug 2021$100M	$190M
Co-investors: Andrew Schwab (5am Ventures), Tony Evnin (Venrock)
Wugen	Series BJul 2021$170M	$170M
Co-investors: John McKearn (RiverVest)
Glycomine	Series BJun 2021$35M	$35M
Co-investors: Jim Trenkle (Sanofi Ventures), Niall O’Donnell (RiverVest)
Reneo Pharmaceuticals	Series BDec 2020$95M	$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Niall O’Donnell (RiverVest)
NuCana BioMed	Post Ipo EquityOct 2020$80M	$140M
Co-investors: James Healy (Sofinnova Investments)
Spruce Biosciences	Series BFeb 2020$88M	$88M

Investors who invest with Bali Muralidhar

Andrew Sinclair

Brian Gallagher

Jacqueline Grant